ArticleEcancermedicalscience2016
The incidence and mortality of ovarian cancer and their relationship with the Human Development Index in Asia.
Article in Ecancermedicalscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- The burden of ovarian cancer attributable to occupational asbestos exposure in Asia from 1990 to 2021: an analysis of the global burden of disease study 2021.Tropical medicine and health · 2026Article
- A Decade of Ovarian Cancer in Indonesia: Epidemiology and Survival Analysis from 2010 to 2020.Journal of clinical medicine · 2025Article
- Observational
- Case report: Malignant transformation of ovarian endometrioma during long term use of dienogest in a young lady.Frontiers in oncology · 2024Article
- The impact of pathogenicSAGE open medicine · 2024Article
- Burden of esophageal cancer between 2010 and 2019 in Asian countries by geographical region and sociodemographic index: A comparison with global data.Thoracic cancer · 2023Article
- Article
- Use of Period Analysis to Timely Assess Five-Year Relative Survival for Patients with Ovarian Cancer from Taizhou, Eastern China.Journal of clinical medicine · 2023Article
- Ovarian Cancer in Iran: National Based Study.Iranian journal of public health · 2023Article
- Global, Regional, and National Incidence and Disability-Adjusted Life-Years for Urolithiasis in 195 Countries and Territories, 1990-2019: Results from the Global Burden of Disease Study 2019.Journal of clinical medicine · 2023Article
- Acute kidney injury after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer.Frontiers in oncology · 2023Article
- Preparation of triangular silver nanoparticles and their biological effects in the treatment of ovarian cancer.Journal of ovarian research · 2022Article
- Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?South Asian journal of cancer · 2022Article
- Incidence, Mortality and Survival Analysis of Epithelial Ovarian Cancer in Brunei Darussalam.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Pathological Features of Ovarian Tumors, Diagnosed at a Tertiary Care Hospital in Afghanistan: A Cross-sectional Study.Cancer management and research · 2022Article
- Predictive value of preoperative inflammatory markers and serum CA 125 level for surgical outcome in Indonesian women with epithelial ovarian cancer.Cancer biomarkers : section A of Disease markers · 2022Article
- CD133 Act as an Essential Marker in Ovarian Carcinogenesis.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Worldwide incidence and mortality of ovarian cancer and Human Development Index (HDI): GLOBOCAN sources and methods 2018.Journal of preventive medicine and hygiene · 2021Article
- Oncogenes in high grade serous adenocarcinoma of the ovary.Genes & cancer · 2020Article
- MassArray analysis of genomic susceptibility variants in ovarian cancer.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence and mortality estimates of ovarian cancer based on human development are essential for planning by policy makers. This study is aimed at investigating the standardised incidence rates (SIR) and standardised mortality rates (SMR) of ovarian cancer and their relationship with the Human Development Index (HDI) in Asian countries.
methodsThis study was an ecologic study in Asia for assessment of the correlation between SIR, age standardised rates (ASR), and HDI and their details, including life expectancy at birth, mean years of schooling, and gross national income (GNI) per capita. We used the correlation bivariate method for assessment of the correlation between ASR and HDI, and its details. Statistical significance was assumed if P < 0.05. All reported P-values were two-sided. Statistical analyses were performed using SPSS (Version 15.0, SPSS Inc.).
resultsThe highest SIR of ovarian cancer was observed in Singapore, Kazakhstan, and Brunei respectively. Indonesia, Brunei, and Afghanistan had the highest SMR. There was a positive correlation between the HDI and SIR (r = 0.143, p = 0.006). Correlation between SMR of ovarian cancer and HDI was not significant (r = 0.005, p = 052.0).
conclusionAccording to the findings of this study, between the HDI and SIR, there was a positive correlation, but there was no correlation between the SMR and HDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.